iSTAR Medical completes enrolment of first-in-human MIGS trial

Wavre, Belgium: 17 October 2017 - iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, announced today the completion of enrolment in their first-in-human (FIH) micro-invasive glaucoma surgery (MIGS) trial for the MINIjectTM device. 

The FIH trial is a prospective, open, international, multi-centre study which has recruited 25 patients with mild-to-moderate, open angle glaucoma uncontrolled by topical hypotensive medications for implantation with a MINIject device. Patient enrolment occurred in centres between June and October 2017. The aim of this study is to assess the safety and performance of the MINIject device measured by intra-ocular pressure (IOP) reduction under medication from baseline to 6 months. Subsequent safety and performance will be measured at 12 and 24 months post-surgery. 

More info on iSTAR Medical's website.


Next > Emmanuel Blin named Chairman of the Board at Noona Healthcare

Previous > Arkite raises € 1.6 million to accelerate its European expansion